21 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 18 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 18 |
| Phase 2 | 8 | Completed 5, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Vaxart: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T - Norovirus Infections | Phase 1 | Completed | Vaxart | 60 | 2025-03-03 | 2026-07-27 |
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 - SARS-CoV2, COVID-19 | Phase 2 | Active not recruiting | Vaxart | 5485 | 2024-10-08 | 2026-10-09 |
| A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infections | Phase 1 | Completed | Vaxart | 76 | 2023-10-27 | 2026-04-15 |
| A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose - Norovirus Infections | Phase 2 | Completed | Vaxart | 135 | 2023-01-26 | 2025-04-15 |
| A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers VXA-G1.1-NN - Norovirus Infections | Phase 1 | Completed | Vaxart | 8 | 2022-01-24 | 2024-06-21 |
| Norovirus Challenge Study VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum - Norovirus Infections | Phase 1 / Phase 2 | Completed | Vaxart | 165 | 2021-12-27 | 2025-11-05 |
| A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine VXA-CoV2-1.1-S, Placebo Tablets - COVID-19 | Phase 2 | Terminated | Vaxart | 66 | 2021-10-22 | 2025-04-13 |
| Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines VXA-G1.1-NN - Norovirus Infections | Phase 1 / Phase 2 | Completed | Vaxart | 30 | 2021-04-30 | 2024-05-22 |
| Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine VXA-GI.1.NN, Placebo Tablet - Norovirus Infections | Phase 1 | Completed | Vaxart | 66 | 2021-04-26 | 2023-02-13 |
| Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects VXA-CoV2-1 - Covid19 | Phase 1 | Completed | Vaxart | 35 | 2020-09-21 | 2024-06-21 |
| Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infection | Phase 1 | Completed | Vaxart | 86 | 2019-03-20 | 2022-09-21 |
| Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model Norwalk GI.1 Virus - Norovirus Infection | Phase 1 | Completed | WCCT Global | 16 | 2018-10-03 | 2020-01-22 |
| Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers VXA-G1.1-NN Oral Vaccine - Norovirus Gastroenteritis | Phase 1 | Completed | Vaxart | 66 | 2017-04-07 | 2018-05-30 |
| Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large) - Seasonal Influenza Preventative Vaccine Pharmacodynamics | Phase 1 | Completed | Vaxart | 8 | 2017-03-31 | 2018-05-30 |
| A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine VXA-A1.1, Fluzone®, Placebo Tablets - Influenza | Phase 2 | Completed | Vaxart | 179 | 2016-08-31 | 2022-10-06 |
| Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet - Norovirus Gastroenteritis | Phase 1 | Completed | Vaxart | 66 | 2016-07-29 | 2018-05-31 |
| Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f) VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose) - Respiratory Syncytial Virus (RSV) | Phase 1 | Completed | Vaxart | 66 | 2016-06-22 | 2018-08-16 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients AP611074 5% gel, AP611074 matching placebo - Condyloma | Phase 2 | Completed | Vaxart | 218 | 2016-01-01 | 2018-07-20 |
| Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine, Placebo Tablets - Seasonal Influenza B | Phase 1 | Completed | Vaxart | 54 | 2015-10-20 | 2018-05-31 |
| Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum VXA-A1.1 - Seasonal Influenza | Phase 1 | Completed | Vaxart | 37 | 2013-01-01 | 2014-12-10 |
Showing 20 of 24. Sign in to see all of them.
Caliciviridae Infections (9) · COVID-19 (3) · Influenza, Human (3) · Influenza in Birds (2) · Condylomata Acuminata (1) · Papillomavirus Infections (1) · Respiratory Tract Infections (1) · Sexually Transmitted Diseases (1) · Virus Diseases (1)
Vaccines (3) · BNT162 Vaccine (1) · Gels (1) · Influenza Vaccines (1) · Saline Solution (1) · Sodium Chloride (1) · VXA-CoV2-1 vaccine (1) · VXA-CoV2-1.1-S vaccine (1)
United States (20) · Argentina (1) · Chile (1) · Ecuador (1) · New Zealand (1) · Serbia (1) · South Africa (1)
David Liebowitz, MD, PhD (6) · James Cummings, MD (6) · Anna Novotney-Barry (2) · Apinya Vutikullird, DO (1) · Helen Paguntalan, MD (1) · Laura Sterling, MD (1) · Laura Sterling, MD, PhD (1) · Martin Kabongo, MD, PhD (1) · Mary Beth Manning, MD (1) · Sean N Tucker, PhD (1) · Sean Tucker, PhD (1) · Walter Doll, PhD (1)
PMID 23357198, PMID 26333337, PMID 29997294, PMID 31978354, PMID 33632249, PMID 35511920, PMID 40043138